Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis

Head and neck squamous cell carcinoma remains challenging to treat with no improvement in survival rates over the past 50 years. Thus, there is an urgent need to discover more reliable therapeutic targets and biomarkers for HNSCC. Matriptase, a type-II transmembrane serine protease, induces malignant transformation in epithelial stem cells through proteolytic activation of pro-HGF and PAR-2, triggering PI3K-AKT-mTOR and NFKB signaling. The serine protease inhibitor lympho-epithelial Kazal-type-related inhibitor (LEKTI) inhibits the matriptase-driven proteolytic pathway, directly blocking kallikreins in epithelial differentiation. Hence, we hypothesized LEKTI could inhibit matriptase-dependent squamous cell carcinogenesis, thus implicating kallikreins in this process. Double-transgenic mice with simultaneous expression of matriptase and LEKTI under the keratin-5 promoter showed a prominent rescue of K5-Matriptase premalignant phenotype. Notably, in DMBA-induced SCC, heterotopic co-expression of LEKTI and matriptase delayed matriptase-driven tumor incidence and progression. Co-expression of LEKTI reverted altered Kallikrein-5 expression observed in the skin of K5-Matriptase mice, indicating that matriptase-dependent proteolytic pathway inhibition by LEKTI occurs through kallikreins. Moreover, we showed that Kallikrein-5 is necessary for PAR-2-mediated IL-8 release, YAP1-TAZ/TEAD activation, and matriptase-mediated oral squamous cell carcinoma migration. Collectively, our data identify a third signaling pathway for matriptase-dependent carcinogenesis in vivo. These findings are critical for the identification of more reliable biomarkers and effective therapeutic targets in Head and Neck cancer.

Citing Articles

TEAD transcription factor family emerges as a promising therapeutic target for oral squamous cell carcinoma.

Wang S, Shao D, Gao X, Zhao P, Kong F, Deng J Front Immunol. 2024; 15:1480701.

PMID: 39430767 PMC: 11486717. DOI: 10.3389/fimmu.2024.1480701.

Translational and Comparative Research on Innovative Anti-Cancer Therapies.

Queiroga F, Cogliati B Cancers (Basel). 2023; 15(4).

PMID: 36831676 PMC: 9954087. DOI: 10.3390/cancers15041335.

IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N-methyladenosine-dependent binding.

Zhang J, Yang K, Bu J, Yan J, Hu X, Liu K Front Oncol. 2022; 12:1035871.

PMID: 36313631 PMC: 9606626. DOI: 10.3389/fonc.2022.1035871.

SPINKs in Tumors: Potential Therapeutic Targets.

Liao C, Wang Q, An J, Zhang M, Chen J, Li X Front Oncol. 2022; 12:833741.

PMID: 35223512 PMC: 8873584. DOI: 10.3389/fonc.2022.833741.

References

Leusink F, van Diest P, Frank M, Broekhuizen R, Braunius W, van Hooff S . The Co-Expression of Kallikrein 5 and Kallikrein 7 Associates with Poor Survival in Non-HPV Oral Squamous-Cell Carcinoma. Pathobiology. 2015; 82(2):58-67. DOI: 10.1159/000381904. View

Sales K, Friis S, Abusleme L, Moutsopoulos N, Bugge T . Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors. Oncogene. 2014; 34(35):4664-72. PMC: 4459940. DOI: 10.1038/onc.2014.391. View

Gioanni J, Fischel J, Lambert J, Demard F, Mazeau C, Zanghellini E . Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol. 1988; 24(9):1445-55. DOI: 10.1016/0277-5379(88)90335-5. View

Yousef G, Diamandis E . Tissue kallikreins: new players in normal and abnormal cell growth?. Thromb Haemost. 2003; 90(1):7-16. View

Bagan J, Scully C . Recent advances in Oral Oncology 2007: epidemiology, aetiopathogenesis, diagnosis and prognostication. Oral Oncol. 2008; 44(2):103-8. DOI: 10.1016/j.oraloncology.2008.01.008. View

Shaw J, Diamandis E . Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007; 53(8):1423-32. DOI: 10.1373/clinchem.2007.088104. View

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T . Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676-82. PMC: 3855844. DOI: 10.1038/nmeth.2019. View

Sales K, Masedunskas A, Bey A, Rasmussen A, Weigert R, List K . Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat Genet. 2010; 42(8):676-83. PMC: 3081165. DOI: 10.1038/ng.629. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

10.

Maehama T, Nishio M, Otani J, Mak T, Suzuki A . The role of Hippo-YAP signaling in squamous cell carcinomas. Cancer Sci. 2020; 112(1):51-60. PMC: 7780025. DOI: 10.1111/cas.14725. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Fortelny N, Cox J, Kappelhoff R, Starr A, Lange P, Pavlidis P . Network analyses reveal pervasive functional regulation between proteases in the human protease web. PLoS Biol. 2014; 12(5):e1001869. PMC: 4035269. DOI: 10.1371/journal.pbio.1001869. View

13.

Sun P, Xue L, Song Y, Mao X, Chen L, Dong B . Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells. Oncotarget. 2018; 9(16):12682-12694. PMC: 5849165. DOI: 10.18632/oncotarget.23913. View

14.

Pawar N, Buzza M, Antalis T . Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression. Cancer Res. 2019; 79(2):301-310. PMC: 6335149. DOI: 10.1158/0008-5472.CAN-18-1745. View

15.

Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky D . PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma. Sci Rep. 2019; 9(1):1844. PMC: 6372636. DOI: 10.1038/s41598-018-38362-0. View

16.

Nishio M, Maehama T, Goto H, Nakatani K, Kato W, Omori H . Hippo vs. Crab: tissue-specific functions of the mammalian Hippo pathway. Genes Cells. 2017; 22(1):6-31. DOI: 10.1111/gtc.12461. View

17.

Szabo R, Rasmussen A, Moyer A, Kosa P, Schafer J, Molinolo A . c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene. 2011; 30(17):2003-16. PMC: 3084339. DOI: 10.1038/onc.2010.586. View

18.

Johnson J, Miller D, Jiang R, Liu Y, Shi Z, Tarwater L . Protease-activated Receptor-2 (PAR-2)-mediated Nf-κB Activation Suppresses Inflammation-associated Tumor Suppressor MicroRNAs in Oral Squamous Cell Carcinoma. J Biol Chem. 2016; 291(13):6936-45. PMC: 4807278. DOI: 10.1074/jbc.M115.692640. View

19.

Gonzalez H, Gujrati M, Frederick M, Henderson Y, Arumugam J, Spring P . Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2003; 129(7):754-9. DOI: 10.1001/archotol.129.7.754. View

20.

Forastiere A, Koch W, Trotti A, Sidransky D . Head and neck cancer. N Engl J Med. 2002; 345(26):1890-900. DOI: 10.1056/NEJMra001375. View